Inhibitors of Neutrophil Recruitment Identified Using Transgenic Zebrafish to Screen a Natural Product Library by Wang, Xingang et al.
 
Inhibitors of Neutrophil Recruitment Identified Using Transgenic
Zebrafish to Screen a Natural Product Library
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Wang, Xingang, Anne L. Robertson, Jingyu Li, Ruth Jinfen Chai,
Wang Haishan, Pranvera Sadiku, Nikolay V. Ogryzko, et al. 2013.
“Inhibitors of Neutrophil Recruitment Identified Using Transgenic
Zebrafish to Screen a Natural Product Library.” Disease Models &
Mechanisms 7 (1) (November 28): 163–169.
doi:10.1242/dmm.012047. http://dx.doi.org/10.1242/dmm.012047.
Published Version doi:10.1242/dmm.012047
Accessed February 17, 2015 2:08:20 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13342796
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA© 2014. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2014) 7, 163-169 doi:10.1242/dmm.012047
163
ABSTRACT
Cell migration is fundamental to the inflammatory response, but
uncontrolled cell migration and excess recruitment of neutrophils and
other leukocytes can cause damage to the tissue. Here we describe
the use of an in vivo model – the Tg(mpx:GFP)i114 zebrafish line, in
which neutrophils are labelled by green fluorescent protein (GFP) –
to screen a natural product library for compounds that can affect
neutrophil migratory behaviour. Among 1040 fungal extracts
screened, two were found to inhibit neutrophil migration completely.
Subfractionation of these extracts identified sterigmatocystin and
antibiotic PF1052 as the active components. Using the EZ-TAXIScan
chemotaxis assay, both compounds were also found to have a
dosage-dependent inhibitory effect on murine neutrophil migration.
Furthermore, neutrophils treated with PF1052 failed to form
pseudopods and appeared round in shape, suggesting a defect in
PI3-kinase (PI3K) signalling. We generated a transgenic neutrophil-
specific PtdIns(3,4,5)P3 (PIP3) reporter zebrafish line, which revealed
that PF1052 does not affect the activation of PI3K at the plasma
membrane. In human neutrophils, PF1052 neither induced apoptosis
nor blocked AKT phosphorylation. In conclusion, we have identified
an antibiotic from a natural product library with potent anti-
inflammatory properties, and have established the utility of the
mpx:GFP transgenic zebrafish for high-throughput in vivo screens for
novel inhibitors of neutrophil migration.
KEY WORDS: Neutrophil, Recruitment, Migration, Drug screen,
Zebrafish
INTRODUCTION
Neutrophils constitute about 40-60% of circulating white blood cells
in the human body and are the first line of cellular defence against
foreign pathogens deployed by the innate immune system.
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Neutrophils migrate rapidly to sites of infection or injury in response
to diverse chemo-attractants, including N-formyl-methionine-
leucine-phenylalanine (fMLF), interleukin-8 and reactive oxygen
species (Clark and Klebanoff, 1979; Ellett et al., 2011; Hattori et al.,
2010; Lekstrom-Himes et al., 2005). As the insult is contained, the
inflammatory response is resolved through reverse migration of
neutrophils (Mathias et al., 2006) or by their apoptosis followed by
macrophage engulfment (Bratton and Henson, 2011). Uncontrolled
neutrophilic activity and continued recruitment of neutrophils to
inflammatory sites can result in persistent inflammation, a feature
of many human diseases, including chronic obstructive pulmonary
disease (COPD) and cystic fibrosis (reviewed by Gernez et al.,
2010). Inhaled bronchodilators and corticosteroids are prescribed for
COPD, largely for symptom control, but these drugs are, for the
most part, ineffective in controlling inflammation and halting
disease progression (Morjaria et al., 2010). There is thus a pressing
need for novel drugs that specifically target neutrophils.
The zebrafish has emerged as a powerful model not only for the
study of vertebrate development but also for high-throughput drug
discovery, facilitated by their small transparent embryos that can
readily be arrayed into 96-well plates. The generation of transgenic
zebrafish expressing neutrophil-specific GFP reporters has made
possible the in vivo analysis of neutrophil behaviour (Renshaw et al.,
2006; Mathias et al., 2006). Like their human counterparts, zebrafish
neutrophils migrate towards the wound site in a PI3K-signalling-
dependent manner (Yoo et al., 2010) and clear microbes by
phagocytosis (Colucci-Guyon et al., 2011). The removal of
neutrophils by reverse migration as well as by apoptosis and
macrophage uptake has also been observed during inflammation
resolution (Ellett et al., 2011; Loynes et al., 2010).
Here we describe the use of one such transgenic zebrafish
neutrophil-specific reporter line in an in vivo screen of natural
product extracts for inhibitors of neutrophil recruitment. We report
the identification of two inhibitory compounds using this zebrafish
model and their validation using an established in vitro mammalian
neutrophil migration assay.
RESULTS
Tailfin resection-induced migration provides a robust in vivo
screening assay
Our aim was to establish an assay for the rapid identification of
highly effective inhibitors of neutrophil migration. To this end, we
constructed an assay protocol based on rapid visual assessment of
neutrophil recruitment. Targeted expression of GFP, using the
myeloperoxidase (mpx) or lysozyme C (lyz) promoters (Renshaw et
al., 2006; Hall et al., 2007), reveals the anterior yolk sac and
posterior intermediate cell mass (ICM) of living zebrafish larvae to
be the origin of neutrophils. In uninjured larvae, caudal neutrophils
remain along the ventral side (Fig. 1A) but, following tailfin
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amputation, they rapidly migrate towards the wound site. By 3 hours
after amputation, ~ten neutrophils are recruited to the distal portion
of the remaining tailfin (Fig. 1B). To determine whether this assay
could be used to screen for compounds that affect neutrophilic
migration, rather than those that accelerate inflammation resolution
(Ellett et al., 2011; Loynes et al., 2010), 2- to 3-day post-fertilisation
(dpf) larvae were pre-incubated with the known PI3K inhibitor
LY294002 and microtubule inhibitor nocodazole for 1, 3 or 5 hours
prior to tailfin transection, and subsequently transferred into fresh
drug-containing media for a further 3 hours before analysis of
neutrophil recruitment to the wound site (see Materials and
Methods). We found that both LY294002 (50 μM) and nocodazole
(33  μM) were effective in inhibiting neutrophil migration
(Fig. 1C,D,I) after 3 or 5 hours of pre-incubation. Because there
were more toxic effects following 5 hours of pre-incubation, we
used a 3-hour pre-incubation for the screening protocol.
A screen of fungal extracts uncovers naturally occurring
neutrophil inhibitors
Using the tailfin transection assay, we screened a library of 1040
crude fungal extracts from the MerLion collection, a diverse
assortment of natural products obtained from a variety of sources.
From this library, we identified 35 candidate samples that met our
predetermined criteria and further validation of these 35 samples
confirmed that two of them produce consistent inhibitory effects (see
supplementary material Table S1). The first of these, XF06-5B03,
completely inhibited all neutrophil migration to the wound site
(Fig. 1E). This extract was derived from an ascomycete of the genus
Sphaeropsidales, isolated from a soil sample collected in Singapore.
The second extract, XF06-2A10, derived from the Aspergillus
genus, similarly inhibited neutrophil recruitment (Fig. 1G).
Identification of antibiotic PF1052 and sterigmatocystin as
neutrophil migration inhibitors
A major challenge posed by screening a natural product library is
the identification of the active component in the biological mixture.
To identify the active component(s) identified by the tailfin assay,
each extract was fractionated by high performance liquid
chromatography (HPLC) into 38 fractions. Remarkably, only a
single fraction of XF06-5B03 produced the same response as the
crude extract. Liquid-chromatography–mass-spectrometry (LC-MS)
analysis of the active fraction identified a chemical structure
corresponding to a compound within the MerLion Pharmaceuticals
purified natural product compound library. This compound, termed
RESEARCH REPORT Disease Models & Mechanisms (2014) doi:10.1242/dmm.012047
TRANSLATIONAL IMPACT
Clinical issue
Neutrophil-mediated inflammation is a feature of a diverse range of
diseases, including chronic obstructive pulmonary disease (COPD),
kidney disease, inflammatory bowel disease and neutrophilic dermatoses
(a group of skin disorders). Collectively, these diseases are a major
threat to global health: COPD alone is currently the fifth biggest killer
globally and is predicted by the WHO to rise to the third position by 2020.
This is exacerbated by the complete lack of compounds that target the
neutrophil in clinical practice, highlighting an area of huge unmet need.
Existing approaches to drug discovery rely on identification of targets,
drugging those targets using compounds from pharmaceutical libraries,
and then determining the cellular phenotype. By contrast, a phenotype-
based screen is utilised here to identify compounds with anti-
inflammatory actions from natural compound libraries. 
Results
This report describes the development of a rapid assay for the
identification of compounds with activity against neutrophil recruitment
following tissue injury in zebrafish expressing GFP-labelled neutrophils.
Using this assay on a carefully chosen library of fungi-derived natural
products, followed by fractionation and mass spectrometry, two
compounds, including one antibiotic, were identified with profound effects
on neutrophil recruitment in vivo. Both compounds were also found to
have inhibitory effects on murine neutrophil migration in vitro. Using a
newly generated transgenic zebrafish line, differences in activity between
antibiotic PF1052 and inhibitors of phosphoinositide 3-kinases (a family
of enzymes with multiple cellular roles) were identified, suggesting that
PF1052 acts independently of these signalling pathways. 
Implications and future directions
These findings demonstrate that zebrafish can be used for robust in vivo
assessments of compound activity at a level of throughput that facilitates
drug discovery. Furthermore, this study shows that pure and highly active
compounds can be identified from natural product extracts and their
mechanism of action can be explored in vivo. Finally, the compounds
identified might have value for elucidating the mechanisms of neutrophil
chemotaxis in the context of disease, and represent viable candidates to
lead future programmes of anti-inflammatory drug discovery.
Fig.1. Inhibitory effect of PF1052 and sterigmatocystin on neutrophil
migration towards the wound site. Neutrophil migration assay was carried
out using Tg(mpx:GFP)i114 larvae according to Renshaw et al. (Renshaw et
al., 2006). (A) Neutrophils were quiescent on an uninjured 3-dpf larva.
(B) About ten neutrophils were recruited to the wound site 3hours after the
tailfin was amputated on a control larva that was treated with DMSO.
(C,D) Larvae treated by PI3K inhibitor LY294002 (50μM) or microtubule
inhibitor nocodazole (33μM), respectively, had few neutrophils recruited to
the wound. (E) An extract (ID: XF06-5B03) from an ascomycete genus
Sphaeropsidales completely blocked neutrophil migration towards the wound
at 50 μg/ml. (F) The active component identified from XF06-5B03 extract
(PF1052) also completely blocked neutrophils recruitment at a very low
concentration of 2 μM; the molecular structure of PF1052 is shown in J.
(G,H,K) Another extract, XF06-2A10, from a fungus, genus Aspergillus, that
blocked the migration of neutrophils contains the functional component
sterigmatocystin, working at 50 μM. (I) Quantification of neutrophils recruited
to the site of injury (n>15). The white line on B-H indicates the amputation
site of tailfin. ***P<0.001.
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(Fig. 1J) first described by Meiji Seika Kaisha, Ltd as having
antimicrobial properties (Sasaki et al., 1992). A small amount of the
pure compound was obtained for further evaluation and confirmed
as being the active component within the fraction. We also
purchased PF1052 from an independent source (Enzo Life Sciences)
and verified its activity as a highly effective neutrophil migration
inhibitor, with an effective concentration as low as 2 μM (Fig. 1F,I).
Fractionation and LC-MS analysis of the second extract, XF06-
2A10, revealed its active component to be sterigmatocystin
(Fig. 1L). Pure sterigmatocystin powder purchased from Sigma-
Aldrich reproduced the effect of XF06-2A10 at 50 μM, confirming
its identity as the active component (Fig. 1H,I).
PF1052 works as antibiotic on bacteria in vitro at 2.3 mM (Koyama
et al., 2005). We tested whether this concentration was comparable to
that within the embryos by performing LC-MS analysis of zebrafish
larvae pre-treated for 3 hours. Using LC-MS analysis, we found that
absorption of PF1502 by zebrafish larvae was rapid, the concentration
reaching 219 μM by 3 hours and 301 μM by 6 hours, with a
concomitant fall in media concentration from 2 μM to 0.67 and
0.44 μM, respectively (Table 1). Larvae incubated in 50 μM
sterigmatocystin had concentrations of 870 and 704 μM by 3 and
6 hours, respectively. The concentration of PF1052 is much lower than
the published effective antibiotic concentration, suggesting a different
mechanism for its neutrophil migration inhibitory effects.
Effects of PF1052 and sterigmatocystin on mammalian
neutrophil migration
We next asked whether the compounds identified using the zebrafish
assay could also inhibit the migration of mammalian neutrophils
using an EZ-TAXIScan chemotaxis device, in which a stable
chemo-attractant gradient is formed in a 260-μm-wide channel
(Fig. 2A). Freshly purified mouse neutrophils (treated with DMSO
as control) migrated robustly up the gradient (see supplementary
material Movie 1). By contrast, fMLF (a formyl peptide)-induced
chemotaxis of neutrophils exposed to 10 μM PF1052 or 100 μM
sterigmatocystin was severely compromised, with most neutrophils
losing motility and polarity. Although a few cells managed to
migrate out, they showed a lack of directionality and slow migration
up the chemo-attractant gradient (Fig. 2B,C; also see supplementary
material Movies 2 and 3). The effect was concentration dependent,
with 20 μM PF1052 and 200 μM sterigmatocystin having a stronger
effect (Fig. 2A; also see supplementary material Movies 4 and 5).
PF1052 is a specific inhibitor of neutrophil migration
Because sterigmatocystin is both hepatotoxic and carcinogenic, we
excluded it from further analysis and focused exclusively on
PF1052. To investigate whether the effect of PF1052 on migration
is specific to neutrophils, we monitored macrophage migration to a
tailfin wound in PF1052-treated larvae and found no difference
between treated and control animals (Fig. 3A,B). This is consistent
with the inhibitory activity of PF1052 being specific to neutrophils
rather than a general effect on innate immune cell migration.
To confirm that PF1052 acts to block the recruitment rather than
the ontogeny of neutrophils, whole-body neutrophil counts were
165
RESEARCH REPORT Disease Models & Mechanisms (2014) doi:10.1242/dmm.012047
Fig.2. PF1052 and sterigmatocystin reduced mouse neutrophil chemotaxis. Mouse neutrophils were pre-treated with 10 μM or 20 μM PF1052, 100 μM or
200 μM sterigmatocystin, or DMSO as control, then were exposed to a chemoattractant gradient generated by addition of 1 μM fMLF (1 μl) in the EZ-TAXIScan
device. (A) Chemotaxis of mouse neutrophils in response to chemoattractant fMLF, both PF1052 (10 μM) and sterigmatocystin (100 μM) severely inhibited
neutrophils migrating upwards, compared with DMSO treatment. At higher concentrations (PF1052 20 μM; sterigmatocystin 200 μM), very few neutrophils
were migratory. (B) Cell tracks of migrating neutrophils (cells that move at least 65 μm from the bottom of the channel) (n=20). (C) Effect of PF1052 and
sterigmatocystin treatment on mouse neutrophil chemotaxis. Neutrophils were evaluated for migration speed, directionality and upward directionality. Results
show the means (±s.d.) of three independent experiments, P<0.05 versus control neutrophils (Student’s t-test).
Table 1. Concentration of compounds in media and zebrafish body 
Compound
Time 
(hours)
Media 
(μmol/l)
Zebrafish 
larvae 
(μmol/kg)
Fold enrichment 
in zebrafish body
PF1052 0 2 0 0
3 0.67±0.06 219±27 327
6 0.44±0.06 301±23 692
Sterigmatocystin 0 50 0 0
3 41.9±2.3 870±15 20.8
6 32.5±0.2 704±48 21.7
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performed in the presence of the active compound or vehicle-only
control. No differences in neutrophil number were observed
following PF1052 treatment and the expected developmental
increase in neutrophil number still occurred in the presence of
PF1052 (Fig. 3C). We also tested the effect of PF1052 on the
viability of human neutrophils in vitro. Human neutrophils cultured
with or without a range of doses of PF1052 were assessed
morphologically for apoptosis. At lower concentrations (200 nM and
2  μM) PF1052 suppressed the apoptosis of isolated human
neutrophils; at higher concentrations, however, this suppressive
effect was lost (Fig. 3D).
PF1052 inhibits neutrophil migration and affects
pseudopodia formation
Using time-lapse imaging, we investigated how PF1052 blocks
neutrophil migration to the wound site. In control larvae, treated
only with DMSO, neutrophils began migrating towards the wound
10 minutes after ventral fin resection. During migration, the cells
actively extended pseudopodia to sense the direction of the wound
site (Fig. 4A,C). By 40 minutes, ~eight neutrophils had been
recruited to the site of injury (red star in Fig. 4A). By contrast, no
neutrophils were recruited to the wound site in PF1052-treated
embryos. They appeared static during the 40 minutes of imaging,
remaining rounded and barely able to form any pseudopodia
(Fig. 4B,D).
PF1052 acts independently of PI3K and AKT activation
The role of PI3K signalling in regulating F-actin polymerisation to
promote neutrophil migration is well established. During migration,
PI3K is localised to the leading edge of neutrophils, catalysing the
phosphorylation of PtdIns(4,5)P2 (PIP2) to generate PtdIns(3,4,5)P3
(PIP3), which binds the PH domain of AKT to activate F-actin
polymerisation at the cell front. To investigate whether PF1052
inhibits PI3K directly, we generated a transgenic line expressing an
in vivo sensor of PIP3 (see Materials and Methods) to probe PI3K
subcellular localisation (Fig. 5A). In Tg(lyz:PHAkt-EGFP)i277
larvae, fluorescent signal accumulated at the leading edge of
neutrophils, usually in the pseudopodia (Fig. 5B). When two
pseudopodia extended from a single neutrophil during chemotaxis,
the one with higher levels of PHAkt-EGFP signal predicted the
direction of migration. In Tg(lyz:PHAkt-EGFP) larvae treated with
the PI3K inhibitor LY294002, accumulation of fluorescent signal
was lost at the leading edge, but instead was dispersed throughout
the cell body (Fig. 5C). By contrast, in larvae treated with XF06-
B03 or PF1052, EGFP signal accumulated at the periphery of the
neutrophils, despite their loss of polarity (Fig. 5D,E).
For a more robust quantification of the effect of PF1052 on
neutrophil polarity, we devised a measurement termed the ‘polarity
index’ that reflects the difference in EGFP intensity at the leading
edge of the cell compared with the trailing edge, as well as the total
fluorescence within the cell. 3-dpf Tg(lyz:PHAkt-EGFP)i277 larvae
RESEARCH REPORT Disease Models & Mechanisms (2014) doi:10.1242/dmm.012047
Fig.3. PF1052 is a specific inhibitor of neutrophil migration.
(A,B) PF1052 has no significant effect on macrophage migration; the MAP
kinase inhibitor SP600125 was used at 30 μM as a positive control. 
(C) PF1052 did not significantly reduce total neutrophil number in intact
larvae. (D) PF1052 does not induce human neutrophil apoptosis and seems
to promote survival at a low concentration (**P<0.01; ***P<0.001; ns, not
significant).
Fig.4. Time-lapse imaging of neutrophil
migration in vivo. The ventral fin of 6-dpf larvae
was injured by a sharp syringe needle, and
chemotaxis of neutrophils were imaged by spinning
disk microscope. (A) In a control larva treated with
DMSO, neutrophil migration was not directed until
10minutes after fin injury. Thereafter, they migrated
actively towards the wound site (red asterisk; 25 and
30 minutes); by 40 minutes after injury, around eight
neutrophils were recruited. (B) In contrast to the
control, neutrophils treated with PF1052 remained
stationary during 40 minutes of imaging; they
appeared round and barely formed any
pseudopods. (C) Higher magnification shows that
DMSO-treated neutrophils actively formed multiple
pseudopods and this was impaired in PF1052
treated-neutrophils (D).
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DMSO control for 3 hours, followed by tailfin transection.
Individual neutrophils were imaged and the fluorescence intensity
was quantified along a longitudinal transection of each cell to
calculate the polarity index (as described in Materials and Methods).
The majority of neutrophils from DMSO-control-treated larvae
appeared polarised, with the most intense EGFP expression in
pseudopodia at their leading edge and only a faint EGFP signal
within the cell body (Fig. 5F). Consistent with our previous
observations, neutrophils from LY294002- or PF1052-treated larvae
did not have a defined leading edge (Fig. 5G,H), which was
reflected in their significantly reduced polarity index compared with
the DMSO control (Fig. 5I).
The pattern of EGFP signal observed in neutrophils from PF1052-
treated larvae indicated that this compound acts independently of
PIP3 generation at the cell membrane. We therefore tested whether
PF1052 prevented the phosphorylation of AKT by inhibition of
activating kinases at the membrane. To investigate this, we
examined expression levels of phosphorylated AKT (p-AKT)
following PF1052 treatment in human neutrophils using western
blotting techniques. We found no change in p-AKT expression in
neutrophils following either 4 or 8 hours culture with PF1052
(Fig. 6A-C). These data, along with our in vivo observations in the
zebrafish, suggest that PF1052 acts independently of the PI3K-Akt
signalling pathway to disrupt leading-edge specification and induce
its inhibitory effect on neutrophil migration.
DISCUSSION
We have successfully used a transgenic zebrafish model in what we
believe to be the first in vivo screen for naturally occurring inhibitors
of neutrophil migration. Through subfractionation and LC-MS
analysis, we identified the antibiotic PF1052 and sterigmatocystin as
the active components of the two fungal extracts showing inhibitory
activity. When applied to mouse neutrophils, both compounds
identified in the zebrafish screen showed a dose-dependent inhibitory
effect on migration, with an inhibition of pseudopod formation similar
to that observed in their zebrafish counterparts. These findings further
validate the utility of the Tg(mpx:GFP)i114 zebrafish as a model
system for the analysis of human neutrophil pathobiology and
illustrate the efficacy of such phenotypic assay systems for screening
complex natural product extract mixtures.
Because sterigmatocystin is reported to have carcinogenic
properties (Ellett et al., 2011), we chose to focus our attention on
PF1052, the therapeutic potential of which has not previously been
explored. PF1052 was initially isolated from fermentation broth of the
fungus Phoma sp. and shown to have antimicrobial activity
(Takahashi et al., 1996). It is structurally closely related to spylidone,
also isolated from Phoma sp. fermentation broth, but unlike spylidone,
PF1052 has no effect on lipid droplet accumulation in macrophages
(Koyama et al., 2005). In this study, we found that PF1052 had no
inhibitory effect on macrophage migration.
The effect of PF1052 on neutrophils was distinct from that of the
PI3K inhibitor LY294002; neutrophils treated with the latter retain
their ability to form thin pseudopods and PHAkt-GFP localises to
the centre of the cell (Yoo et al., 2010). By contrast, treatment with
PF1052 had no effect on Akt phosphorylation or PHAkt-EGFP
localisation but caused loss of polarisation and pseudopod
formation, reflected in the significantly reduced neutrophil ‘polarity
index’. These effects are similar to those caused by a dominant-
negative form of human Rac2D57N or morpholino-mediated
167
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Fig.5. PF1052 inhibited neutrophil
migration in a PI3K-independent manner.
(A) Schematic diagram of the lyz:PHAkt-
EGFP construct used to generate the stable
transgenic line. (B) Time-lapse imaging of
migrating neutrophils showed PHAkt-EGFP
signal was always localised to the cell front
in control larvae. The red signal indicates the
highest level of PI3K at the leading edge.
(C) PI3K inhibitor LY294002 reversed the
cellular localisation of PI3K, which
accumulated within the cell body.
(D,E) Extracts from Sphaeropsidales and its
functional component PF1052 did not affect
the localisation of PI3K at the cell
membrane. (F-I) Quantification of neutrophil
polarity index in DMSO-, LY294002- and
PF1052-treated larvae. LY294002 and
PF1052 significantly reduced neutrophil
polarity index (***P<0.001).
Fig.6. PF1052 does not inhibit AKT
phosphorylation in human neutrophils.
(A) Western blotting shows PF1052 does not
affect AKT phosphorylation in human neutrophils
after either 4 or 8hours culture.
(B,C) Quantification of the level of p-AKT in
untreated, DMSO- and PF1052-treated samples.
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knockdown of Rac2 (Deng et al., 2011). There are also similarities
to the phenotype of mouse neutrophils mutant for SHIP, a Src
homology 2 (SH2)-domain-containing inositol-5-phosphatase,
which hydrolyses PI(3,4,5)P3 to PI(3,4)P2. SHIP was believed to
coordinate with PI3K to determine the localisation of PIP3 and
PIP2, thus controlling neutrophil polarity and motility (Nishio et al.,
2007). In zebrafish, however, knockdown of SHIP leads to an
increase in neutrophil motility and infiltration to the wound, whereas
overexpression of SHIP impairs such migration (Lam et al., 2012).
Although further analysis is needed to resolve the disparity between
these two data sets, we are inclined to argue against an inhibitory
effect of PF1052 on SHIP, based on the findings in zebrafish.
Additional studies will be required to identify the specific target(s)
of PF1052 in neutrophils.
Summary
Here, we demonstrate a feasible in vivo assay for the discovery of
compounds with anti-inflammatory actions from natural compound
libraries. Testing over 40 compounds with suitable positive and
negative controls can easily be accomplished in a day by a single
operator. This screen has identified a novel and highly effective
neutrophil migration inhibitor, PF1052, with the potential to inform
our understanding of neutrophil chemotaxis. We have found that this
compound acts independently of the PI3K and AKT enzymes and
might either act downstream of these molecules or act via other
pathways. Identification of the molecular target has the potential to
reveal a novel target pathway for future drug discovery programmes.
MATERIALS AND METHODS
Zebrafish husbandry
Adult fish were maintained on a 14-hour light/10-hour dark cycle at 28°C
in the AVA certificated IMCB Zebrafish Facility (Singapore). The
Tg(mpx:GFP)i114 line (Renshaw et al., 2006) was used for neutrophil assays.
To investigate macrophage recruitment, we generated a Tg(mpeg1:Gal4.VP-
16)sh256 line as previously described (Ellett et al., 2011) and crossed this to
the Tg(UAS:Kaede)s1999t line (Davison et al., 2007) to generate double-
transgenic larvae expressing green fluorescent Kaede protein under the
macrophage-specific mpeg1 promoter.
Creation of the Tg(lyz:PHAkt-EGFP) line
The 6.6 kb of lysozyme C promoter (Hall et al., 2007) was cloned into a
gateway vector p5E-MCS (Tol2kit). The PH domain of Akt was amplified
from zebrafish cDNA by PCR using forward primer 5′-
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACCATGGGCATGA-
ACGAGATCAGCGTCGT-3′ and reverse primer 5′-GGGGACCAC -
TTTGTACAAGAAAGCTGGGTCACCCAGCAGCTTTAAGTAGTCAA-
3′, and the PCR product was recombined with pDONR 221 (Invitrogen) to
produce pME-PHAkt. The final lyz:PHAkt-EGFP construct was created by
recombination of p5E-lysC, pME-PHAkt, p3E-EGFP and pDestTol2pA2
(Tol2kit) using LR Clonase II plus (Invitrogen). The DNA construct was co-
injected with Tol2 mRNA into one-cell-stage embryos to produce the
transgenic line.
Reagents
The microtubule inhibitor nocodazole (M1404), PI3K inhibitor LY294002
(L9908), sterigmatocystin (S3255) and Tricaine (E10521) were ordered from
Sigma-Aldrich (St Louis, MO). PF1052 (ALX-380-147) was purchased
from Enzo Life Sciences (Farmingdale, NY).
Natural product library
Crude fungal extracts were prepared by fermenting fungal strains in a variety
of growth media and extracting the freeze-dried products of fermentation
using methanol, followed by removal of solvent by rotary and centrifugal
evaporation. 1 mg of each dried crude extract was dispensed per well of a
96-well microtitre plate.
Extract fractionation
The fungal extract was prepared at a concentration of 10 mg/ml in DMSO
and centrifuged at 15,000 g for 2 minutes. An aliquot of extract (up to 800
μg or 80 μl) was analysed by HPLC [Thermos Hypersil BDS C18
4.6×150 mm, 5 μm, solvents: (A) H2O + 0.1% formic acid, (B) MeCN +
0.1% formic acid; gradient: 0 minutes 0% B, 22 minutes; 100% B, 32
minutes; 100% B; flow: 1 ml/minute; 30°C). The eluent from the DAD
(Agilent 1100 with UV detection at 210, 254, 354 and 480 nm) was split in
a 1:10 ratio between an Esquire 3000 ion trap mass spectrometer (Bruker
Daltonik GmbH, Bremen, Germany) and a fraction collector configured to
collect into a 96-well microtitre plate (0.79 minutes/well). A total of 38 wells
were collected (0-30 minutes). The 96-well microtitre plate was dried using
the Genevac HT-8 centrifugal evaporator (8-hour cycle) at 40°C. Wells 39
and 40 were used as controls, which contained 125 μg and 250 μg of crude
extract, respectively. After complete evaporation of the solvent, materials in
the wells were analysed for activity against the tailfin resection assay as
described below. Active fractions were analysed by MS and MS-MS, and
data matched against MerLion’s Esquire compound library, containing mass
spectra records of 2496 compounds that have been analysed under the same
conditions.
Measurement of compound concentration by LC-MS
Zebrafish larvae treated with test compound were mixed with glass beads
and 0.1 M of KH2PO4 buffer (150 μl), and smashed with TOMY Micro
smash MS-100 (4500 rpm, 30 seconds ×4). After adding acetonitrile (350
μl), the mixture was shaken for 30 seconds ×2, and centrifuged at 20,000 g,
4°C, for 10 minutes for two cycles. Supernatant was separated for LC-MS
analysis, which was carried out on a Waters 2795 Separations Module
equipped with a Waters 2996 Photodiode Array (PDA) detector and
micromass Quattro micro mass spectrometer.
Zebrafish in vivo cell migration assays
Tg(mpx:GFP)i114 transgenic zebrafish larvae (2-3 dpf) were first exposed to
extracts in a 96-well plate format, with three larvae per well, containing
200 μl of fish water, 1 mM of Tris pH 7.4, 1% DMSO and 10 μg fungus
extract, at 28°C. Three hours later, the larvae were anaesthetised with
Tricaine and their tailfins amputated using sharp needles to induce the
migration of neutrophils. After injury, the zebrafish larvae were transferred
to fresh extract solution for 3 hours before visual inspection using a
fluorescence stereomicroscope. The number of neutrophils recruited to the
wound site was counted. The effect of PF1052 on macrophage migration was
assessed in the same manner, using the Tg(mpeg:Gal4;UAS:Kaede)sh256 line.
Mouse neutrophil chemotaxis assay
The EZ-TAXIScan chamber (Effector Cell Institute, Tokyo, Japan) was
assembled with a 260 μm wide × 4 μm thick silicon chip on a 2 mm
untreated glass base, as described by the manufacturer, and filled with HBSS
(with Ca2+ and Mg2+)/0.2% BSA. Murine neutrophils were isolated from
bone marrows of 8-week-old male C57BL/6 mice (the Jackson Laboratories,
Bar Harbor, ME). Drug-treated (or DMSO-treated) murine neutrophils (1 μl,
10×106/ml) were added to the lower reservoir of each of the six channels
and allowed to line up by removing 18 μl of buffer from the upper reservoir.
HBSS (with Ca2+ and Mg2+)/0.2% BSA (15 μl with the appropriate
pharmacological inhibitor) was then added to fill both reservoirs, which
were maintained at 37°C. 1 μl of 1 μM chemoattractant (fMLF) was then
added to the upper reservoir and neutrophil migration in each of the channels
was captured sequentially every 30 seconds for 20 minutes using a 10× lens
on a Discovery Screening System (Universal Imaging Corporation,
Downingtown, PA). Drug PF1052 or sterigmatocystin was added directly to
murine neutrophils (100 μl, 10×106/ml) in HBSS (with Ca2+ and Mg2+)/0.2%
BSA and incubated in a 37°C, 5% CO2 chamber for 30 minutes before the
chemotaxis assay.
Analysis of cell tracks and morphology
The (x,y) coordinates of migrating neutrophils (i.e. neutrophils that cross
>65 μm from the starting line) were tracked from sequential images using
DIAS imaging software (Solltech, Oakdale, IA). Cell tracks were then
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plotted using Matlab (MathWorks, Natick, MA). Directionality (0 to 1) is
defined as straight-line migration distance from the origin divided by the
total migration length. Upward directionality (−1 to 1) is defined as straight-
line distance migrated in the upward direction divided by total migration
length. Migration speed (μm/minute) was calculated as the average of cell
speeds (migration distance between the current frame and the previous frame
divided by the time between sequential frames, 0.5 minutes) at each
captured frame.
In vitro apoptosis assay
Neutrophils were isolated from healthy volunteers as previously described
(Wardle et al., 2011), with approval of the South Sheffield Research Ethics
Committee (reference number: STH13927). Neutrophils were cultured with
DMSO, or 0.2, 2 or 20 μM PF1052 for 8 hours at 37°C, and apoptosis was
assessed by morphology on cytospins stained with Quick-Diff (Gentaur,
Brussels, Belgium).
Detection of p-AKT by western blot analysis
Neutrophils were isolated and cultured as described above, for either 4 or
8 hours, with 2×106 cells per condition. Cells were lysed as previously
described (Wardle et al., 2011) and western blotting was performed
according to standard protocols (Sambrook, 1989). Antibodies used were
anti-phospho-Akt (Ser473) (Cell Signaling, Herts, UK) at 1:1000, or anti-β-
actin (Sigma-Aldrich, Poole, UK) at 1:4000, with polyclonal goat anti-rabbit
secondary antibody (Dako, UK) at 1:2000. To analyse changes in protein
expression, densitometry was performed using ImageJ, as previously
described (Wardle et al., 2011).
Imaging of zebrafish neutrophil migration in vivo
For time-lapse imaging, Tg(lyz:PHAkt-EGFP)i277 zebrafish larvae were
anaesthetised with 0.02% Tricaine and embedded in 1% low melting agarose
on a depression slide. Embedded larvae were then placed under a 40× water
objective, immersed in water containing Tricaine. Images were captured
every 15 seconds, using an Olympus spinning disc fluorescence microscope
(BX61) or Olympus Confocal microscope (BX61). To assess the effects of
PF1052 on neutrophil polarity, Tg(lyz:PHAkt-EGFP)i277 larvae were pre-
incubated with either 2 μM PF1052, 50 μM LY294002 or DMSO control
for 2 hours prior to tailfin transection and mounting. Images of individual
neutrophils in the region between the injury site and the posterior blood
island were captured using an UltraVIEWVoX spinning disk confocal
imaging system (PerkinElmer Life and Analytical Sciences) with an inverted
Olympus IX81 microscope, at 60× magnification with ten Z slices. Images
were analysed in ImageJ, by drawing a transection through each neutrophil
from the trailing edge towards the leading edge. In cases where there were
no clear leading or trailing edges, the line was drawn through the most
longitudinal section of the cell. A plot profile was generated to measure the
fluorescence intensity per pixel along the length of the line and the mean
intensities along sections of this line (as defined in Fig. 5A) were used to
calculate the polarity index, with the equation: 
Statistical analysis
Data were analysed in GraphPad Prism 5.0 using one-way ANOVA with
appropriate post-test adjustment.
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sMovie S1. fMLF-induced mouse neutrophil chemotaxis treated by DMSO.
Movie S2. Inhibitory effects of PF1052 on mouse neutrophil chemotaxis at 10 μM.
Movie S3. Inhibitory effects of Sterigmatocystin on mouse neutrophil chemotaxis at 100 μM.Movie S4. At higher concentration (20 μM), most of PF1052 treated neutrophils remained stationary with a few 
outliers.
Movie S5. Nearly all neutrophils treated by Sterigmatocystin at 200 μM failed to migrate out.Supplementary Table S1. Natural product library ID and candidate hits.  
 
 
Plate ID  Candidate after one round of screening  Confirmed 
XF06-1  A10, E07   
XF06-2  A08,A10,H08  A10 
XF06-3  D08     
XF06-4  D10   
XF06-5  B03,B05 ,C05  B03 
XF06-6  B05,B09   
XF06-7  G04   
XF06-8     
XF06-9     
XP06-1  A10,D01,D02,D03 ,D04 ,D05     
XP06-2  E04,E08,F04 ,F05,F06   
XM01-1  B2,B3,D5,F2,H2,H3,H4,H5   
MB01  B1,B10,C6   
Table S1. Natural product library ID and candidate hits.